any VOD definition, we registered all other conditions that could have caused the clinical findings used as VOD criteria.
Of the 300 patients, 54 had a serum bilirubin concentration exceeding 34 μmol/L within 21 days post transplantation. The peak bilirubin concentration was 35-193 (median 47) μmol/L. Of these patients, 41 showed a weight gain exceeding 2% and 29 a weight gain exceeding 5% of the admission weight. Three additional patients were excluded from the analysis, as the two criteria occurred completely separately, with a period of at least 4 days when neither of the criteria was present. Thus, 41 patients fulfilled the minimum modified Seattle criteria with the 2% weight gain criterion and 29 with the 5% criterion. Two patients had an enlarged liver and right upper quadrant pain and they fulfilled the Baltimore criteria. No case of abnormal venous blood flow was seen. No liver biopsies were done. According to the institutional policy, pre-emptive treatment with defibrotide according to the rising bilirubin levels was started in 10 patients, independent of the fulfillment of the VOD criteria. The treatment was discontinued in a median of 10 (range 1-35) days based on the clinical course. Twenty-six of the 41 patients fulfilling the minimum VOD criteria had other clinical conditions that were regarded by the treating physicians as a plausible cause for the findings. The most common condition (n = 18) was a systemic infection with high fever, a strongly elevated CRP level, and an indication for broad-spectrum antibiotics, with or without an identified causative micro-organism. EBV and CMV infection were regarded as the cause in one patient. Other reasons were engraftment syndrome in two, GvHD in two, drug effect (opioid) in one, cytokine storm after ruxolitinib discontinuation in one, thrombotic microangiopathy in one and cholecystitis in one patient. In the remaining 15 patients no obvious alternative cause was seen for the findings. Thirteen of these cases were mild, showing no hepatomegaly, and they had not been labeled as VOD by the treating physicians.
According to the modified Seattle criteria with the 2% weight increase criterion, 15 patients with no alternative cause had VOD, whereas 26 patients (63%) fulfilling the criteria had an alternative cause and therefore could not be diagnosed as having this disorder. Similarly, with the 5% weight increase criterion, eight patients had VOD, but 21 patients (72%) fulfilling the criteria had an alternative cause and therefore could not be diagnosed as having VOD. Of the two patients fulfilling the Baltimore criteria, one had a simultaneous septic infection, and therefore the diagnosis of VOD could not be confirmed. Thus, depending on the criteria used and according to the differential diagnostic interpretations, the incidence of VOD in this material was between 5 and 0.3%. None of the cases was severe, and no patient died with VOD.
The present analysis shows that differential diagnosis has a marked role in establishing the incidence of VOD. Approximately two thirds of the patients fulfilling the minimum criteria for VOD had an alternative condition that could explain the clinical findings, and were therefore not diagnosed as having VOD. The proportion of patients fulfilling the criteria of the least stringent definition, the modified Seattle criteria with 2% weight increase criterion, was 15%. However, after excluding patients with an alternative cause, only 5% had VOD. Of the two patients who fulfilled the more stringent Baltimore criteria, one could not be diagnosed as having VOD because of a simultaneous systemic infection.
The incidence of VOD in the present patient material was low, with the more stringent Baltimore criteria only one of the 300 patients had this complication. A majority of the other patients with VOD, fulfilling the minimum Seattle criteria, were only afterwards confirmed to have satisfied the definition and they had not been diagnosed as having VOD. However, according to institutional policy, defibrotide administration was initiated in ten patients based on increasing bilirubin levels as a pre-emptive treatment, independent of the fulfillment of the VOD criteria. Besides the pre-emptive defibrotide treatment policy, the low incidence of VOD and the mild presentation may have been due to the use of reduced-toxicity or reduced-intensity conditioning in more than half of the patients as well as to the UDCA prophylaxis which has been shown to reduce hepatic complications in our previous study 6 and VOD in a meta-analysis. 9 With the retrospective approach used, we might have missed an occasional case of VOD where the bilirubin increase was lacking. However, such patients are rare in an adult population.
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Also, we adhered to the time frames of the definitions and did not formally analyse late VOD cases appearing more than three weeks after the transplantation. However, we used the same approach to identify patients fulfilling the minimum VOD criteria after the 3-week period until 2 months post transplantation. No such patients were found.
The present findings suggest, in line with previous experience, Baltimore criteria would be more useful at least in adult patients. The main observation of the present study is that the differential diagnostic interpretations strongly affect the conclusions about the incidence of this complication. In allogeneic transplant patients, several complications including VOD may occur simultaneously, and another condition should not necessarily exclude VOD. It would be of importance to find positive diagnostic indicators for VOD as well as to develop the definitions and criteria of this complication to match the present-day situation. With this aim, the European Society of Blood and Marrow Transplantation has just recently published new revised criteria for VOD. 11 
